Results 161 to 170 of about 61,152 (267)

Mitochondrial Adaptations in Skeletal Muscle Following Incretin‐Based Therapies: In Vitro

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 2, April 2026.
ABSTRACT Background Incretin‐based therapies such as glucagon‐like peptide‐1 receptor agonists (GLP‐1Ras), dual GLP‐1/GIP agonists and amylin analogues have demonstrated significant weight loss benefits. However, their impact on skeletal muscle mitochondrial function, particularly under metabolic stress, remains unclear. This study aimed to investigate
Victoria Old, Melanie Davies, Matthew Denniff, Pratik Choudhary, Nicholas Eastley, Robert U. Ashford, Emma Watson   +6 more
wiley   +1 more source

A DYRK inhibitor ameliorates glucose homeostasis and increases incretin-producing cells in diabetic mice. [PDF]

J Mol Endocrinol
Terasaki M, Zhou Q, Andersson O, Yamagishi SI.   +3 more
europepmc   +1 more source

Import of proteins into mitochondria [PDF]

, 1988
Hartl, Franz-Ulrich, Neupert, Walter, Pfanner, Nikolaus   +2 more
core   +1 more source

Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials

Obesity, Volume 34, Issue 4, Page 770-781, April 2026.
ABSTRACT Objective This study compared the efficacy of metabolic/bariatric surgery (MBS) and GLP‐1 receptor agonists (GLP‐1 RAs), including dual GLP‐1/GIP analogues, for weight and metabolic outcomes in adults with obesity. Methods A network meta‐analysis of randomized controlled trials compared MBS or GLP‐1 RAs versus lifestyle intervention in adults ...
Lucas Sabatella, Patricia M. Ortega, Víctor Valentí Azcárate, Fernando Rotellar Sastre, Adriana Uriz Pagola, Ahmed Ahmed, Sanjay Purkayastha, Carlota Tuero Ojanguren, Nuria Blanco Asensio, Manuel F. Landecho   +9 more
wiley   +1 more source

The Role of Glucose-Dependent Insulinotropic Polypeptide (GIP) in Bone Metabolism. [PDF]

Int J Mol Sci
Lin A, Kitaura H, Ohori F, Marahleh A, Ma J, Fan Z, Narita K, Murakami K, Kanetaka H.   +8 more
europepmc   +1 more source

Trends in Use of Obesity Medications and Metabolic and Bariatric Surgery Among All of Us Participants From 2003 to 2023

Obesity, Volume 34, Issue 4, Page 952-960, April 2026.
ABSTRACT Objective This study aimed to evaluate the trends in antiobesity medication (AOM) and metabolic and bariatric surgery (MBS) use relative to the 2013 American Medical Association (AMA) declaration of obesity as a chronic disease and semaglutide approval in 2021 in the United States.
Olajide A. Adekunle, Phuc Le, Christopher Boyer, Hamlet Gasoyan, Dev Yash Gupta, Ha T. Tran, Yihua Yue, Michael B. Rothberg   +7 more
wiley   +1 more source

Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach

Obesity, Volume 34, Issue 4, Page 851-870, April 2026.
Guidance recommendations by TOS/OMA/OAC for the use of obesity medications to treat obesity and its complications. ABSTRACT Background Obesity affects over 40% of US adults, with severe obesity on the rise. Despite recognition of obesity as a chronic disease, it remains underdiagnosed and undertreated.
Lydia Alexander, Jonathan Q. Purnell, Karlijn Burridge, Marc‐André Cornier, Angela Golden, Deborah Bade Horn, Michelle Look, Joe Nadglowski, Camila Ávila‐Oliver, Francisco Novillo, Ana María Rojas‐Gómez, Brad Hussey, Ximena Ramos Salas   +12 more
wiley   +1 more source

Attitudes Toward Injectable GLP‐1 Drugs for Obesity Treatment: A Qualitative Interview Study With Healthcare Professionals

Obesity Science &Practice, Volume 12, Issue 2, April 2026.
ABSTRACT Background Injectable GLP‐1 drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro, a dual GLP‐1 and GIP receptor agonist) can help individuals living with obesity to lose weight. UK guidelines currently recommend semaglutide and other injectable GLP‐1 drugs are prescribed in specialist (Tier 3) multidisciplinary weight management ...
Raluca C. Capaian, Phillippa Lally, Saskia C. Sanderson   +2 more
wiley   +1 more source

Ginsenoside Rh2- functionalized liposomes enhanced BRD4-PROTAC delivery and antitumor efficacy <i>via</i> improved tumor targeting and ECM remodeling. [PDF]

Mater Today Bio
Wen L, Rao J, Chen J, Li F, Chen X, Guo S, Cui B, Qiu C, Chen W.   +8 more
europepmc   +1 more source

Analysis of Obesity Care in Spanish Healthcare Settings: OBEQUIDAD Study

Obesity Science &Practice, Volume 12, Issue 2, April 2026.
ABSTRACT Background Obesity management remains influenced by misconceptions about the disease, which compromise care quality. Introduction The OBEQUIDAD study explores the clinical management of people with obesity in Spain based on the perspectives of healthcare professionals involved in its treatment across different medical specialties.
Ana de Hollanda, Jennifer Redondo‐Antón, Javier Ágreda, Albert Lecube, José Manuel Fernández‐García, Maria Isabel Pérez Soto, Miriam Rubio‐de Santos, Silvia Díaz‐Cerezo   +7 more
wiley   +1 more source